Astellas wins FDA nod for antifungal Cresemba
This article was originally published in Scrip
Executive Summary
Astellas won the FDA’s approval to market Cresemba (isavuconazonium sulfate) in the US as a treatment for two rare but serious infections, invasive aspergillosis and invasive mucormycosis.